Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yasuhiro Takeuchi

Showing results (321-330 of 324) with videos related to

Pageof 33
Sort By:
You have reached the last page of results.This site can display upto 324 results.
Calcified Tissue International|June 6, 2019
Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled PeriodAnthony A Portale, Thomas O Carpenter, Maria Luisa Brandi, et al.
RMD Open|September 22, 2021
Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extensionKarine Briot, Anthony A Portale, Maria Luisa Brandi, et al.
Nature Medicine|February 18, 2022
The role of antibody responses against glycans in bioprosthetic heart valve calcification and deteriorationThomas Senage, Anu Paul, Thierry Le Tourneau, et al.
Nature|November 16, 2012
Analyses of pig genomes provide insight into porcine demography and evolutionMartien A M Groenen, Alan L Archibald, Hirohide Uenishi, et al.
Pageof 33

Showing results (321-330 of 324) with videos related to

Sort By:
Pageof 33
You have reached the last page of results.This site can display upto 324 results.
Calcified Tissue International|June 6, 2019
Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled PeriodAnthony A Portale, Thomas O Carpenter, Maria Luisa Brandi, et al.
RMD Open|September 22, 2021
Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extensionKarine Briot, Anthony A Portale, Maria Luisa Brandi, et al.
Nature Medicine|February 18, 2022
The role of antibody responses against glycans in bioprosthetic heart valve calcification and deteriorationThomas Senage, Anu Paul, Thierry Le Tourneau, et al.
Nature|November 16, 2012
Analyses of pig genomes provide insight into porcine demography and evolutionMartien A M Groenen, Alan L Archibald, Hirohide Uenishi, et al.
Pageof 33